Table 2 Baseline patient characteristics... | American Society of Hematology

Table 2

Baseline patient characteristics

Study	Age		TTR	Male (%)	Mean CHADS2	Concomitant ASA (%)	Isolated DVT (%)	PE or PE with DVT (%)
Study	TSOACs	VKAs	TTR	Male (%)	Mean CHADS2	Concomitant ASA (%)	Isolated DVT (%)	PE or PE with DVT (%)
1. RE-COVER,⁷ 2009	55.0 ± 15.8*	54.4 ± 16.2*	59.9	58.4	NA	NA	1749 (69)	786 (31)
2. RE-LY,¹² 2009	71.4 ± 8.6* (dabigatran 110), 71.5 ± 8.8* (dabigatran 150)	71.6 ± 8.6*	64	63.6	2.1	39.8%	NA	NA
3. EINSTEIN-DVT,¹⁶ 2010	55.8 ± 16.4*	56.4 ± 16.3*	57.7	56.8	NA	NA	3405 (99)	23 (1)
4. ARISTOTLE,¹³ 2011	70 (63-76)†	70 (63-76)†	62.2	64.7	2.1	5632 (30.9)	NA	NA
5. ROCKET AF,¹⁴ 2012	73 (65-78)†	73 (65-78)†	55	60.3	3.48 (rivaroxaban), 3.46 (warfarin)	5205 (36.5)	NA	NA
6. EINSTEIN-PE,²⁹ 2012	57.9 ± 7.3*	57.5 ± 7.2*	62.7	52.9	NA	NA	0 (0)	4832 (100)
7. J-ROCKET AF,²⁸ 2012	71.0 (34-89)†	71.2 (43-90)†	65	80.6	3.25	NA	NA	NA
8. AMPLIFY,⁸ 2013	57.2 ± 16*	56.7 ± 16*	61	58.7	NA	NA	3532 (65)	1836 (34)
9. ENGAGE-AF-TIMI- 48,¹⁵ 2013	72 (64-78)†	72 (64-78)†	64.9	61.9	2.8	29.3%	NA	NA
10. RE-MEDY,¹¹ 2013	55.4 ± 15.0*	53.9 ± 15.3*	65.3	61	NA	NA	1860 (65.1)	994 (34.8)
11. HOKUSAI-VTE,⁹ 2013	55.7 ± 16.3*	55.9 ± 16.2*	63.5	57.2	NA	NA	4921 (59.7)	3319 (40.3)
12. RE-COVER II,²⁷ 2014	54.7 ± 16.2*	55.1 ± 16.3*	57	60.6	NA	NA	1750 (68.1)	816 (31.8)

Study	Age		TTR	Male (%)	Mean CHADS2	Concomitant ASA (%)	Isolated DVT (%)	PE or PE with DVT (%)
Study	TSOACs	VKAs	TTR	Male (%)	Mean CHADS2	Concomitant ASA (%)	Isolated DVT (%)	PE or PE with DVT (%)
1. RE-COVER,⁷ 2009	55.0 ± 15.8*	54.4 ± 16.2*	59.9	58.4	NA	NA	1749 (69)	786 (31)
2. RE-LY,¹² 2009	71.4 ± 8.6* (dabigatran 110), 71.5 ± 8.8* (dabigatran 150)	71.6 ± 8.6*	64	63.6	2.1	39.8%	NA	NA
3. EINSTEIN-DVT,¹⁶ 2010	55.8 ± 16.4*	56.4 ± 16.3*	57.7	56.8	NA	NA	3405 (99)	23 (1)
4. ARISTOTLE,¹³ 2011	70 (63-76)†	70 (63-76)†	62.2	64.7	2.1	5632 (30.9)	NA	NA
5. ROCKET AF,¹⁴ 2012	73 (65-78)†	73 (65-78)†	55	60.3	3.48 (rivaroxaban), 3.46 (warfarin)	5205 (36.5)	NA	NA
6. EINSTEIN-PE,²⁹ 2012	57.9 ± 7.3*	57.5 ± 7.2*	62.7	52.9	NA	NA	0 (0)	4832 (100)
7. J-ROCKET AF,²⁸ 2012	71.0 (34-89)†	71.2 (43-90)†	65	80.6	3.25	NA	NA	NA
8. AMPLIFY,⁸ 2013	57.2 ± 16*	56.7 ± 16*	61	58.7	NA	NA	3532 (65)	1836 (34)
9. ENGAGE-AF-TIMI- 48,¹⁵ 2013	72 (64-78)†	72 (64-78)†	64.9	61.9	2.8	29.3%	NA	NA
10. RE-MEDY,¹¹ 2013	55.4 ± 15.0*	53.9 ± 15.3*	65.3	61	NA	NA	1860 (65.1)	994 (34.8)
11. HOKUSAI-VTE,⁹ 2013	55.7 ± 16.3*	55.9 ± 16.2*	63.5	57.2	NA	NA	4921 (59.7)	3319 (40.3)
12. RE-COVER II,²⁷ 2014	54.7 ± 16.2*	55.1 ± 16.3*	57	60.6	NA	NA	1750 (68.1)	816 (31.8)

CHADS2 score, 1 is given for point for CHF, HTN, age ≥75 y, and DM; 2 points are given for previous stroke or TIA, and systemic embolism.

ASA, acetylsalicylic acid; NA, not applicable.

Mean ± standard deviation.

Median (minimum-maximum).